The U.S. Food and Drug Administration approved Ann Arbor, Michigan-based Esperion’s Nexlizet (bempedoic acid and ezetimibe) for lowering LDL cholesterol.
The U.S. Food and Drug Administration approved Michigan-based Esperion’s oral, once-daily, non-statin LDL-cholesterol lowering medicine Nexletol (bempedoic acid).
One week after announcing positive data from ORION-10, the second of three 19-month Phase III trials for inclisiran for lowering cholesterol, The Medicines Co. was acquired by Novartis.
Amarin Corp. Plc’s fish oil-derived drug and potential blockbuster Vascepa received a largely positive review from FDA staffers.
High cholesterol is associated with an increased risk of developing glaucoma, but a new study suggests taking statins to lower cholesterol helps to reduce this risk.
Amgen Inc., looking to boost use of the U.S. biotechnology company’s potent cholesterol drug Repatha, cut the medication’s U.S. list price by 60 percent to $5,850.
Australia’s competition watchdog said the High Court dismissed its special leave application to appeal a court’s decision on whether Pfizer Inc.’s local unit used the company’s market power to limit competition for the cholesterol-lowering drug Lipitor.
The U.S. Food and Drug Administration rejected Novartis’ bid to repurpose canakinumab, a drug already approved for rare inflammatory diseases, for use in a group of heart attack survivors.
Celltrion Inc. signed an ‘Incubation’ agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis.
Compared to inactive people, recreational soccer players have lower cholesterol, blood pressure and resting heart rates as well as less fat mass, a research review suggests.